Filgrastim in solid organ transplant recipients

• Autores: Virginia Bosó Ribelles, Eduardo San Martín Ciges, Isabel Font Noguera, Carmen Planells Herrero, José Luis Poveda Andrés
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 3, 2013, págs. 208-212
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Leukopenia is common following solid organ transplantation. This study evaluates the use of filgrastim in solid organ transplant recipients by explicit pharmacotherapeutic criteria. Method: Descriptive and observational study. 26 solid organ transplant recipients were included. Facts related to justification of treatment, effectiveness and safety were assessed. Results: The most likely cause of leukopenia was drugs. Mycophenolate mofetil and valganciclovir were used simultaneously in 50% of the patients. The mean dose of filgrastim was 3.6 mcg/kg/day (95% CI = 2.8-4.4). The median length of therapy was seven days (range 4.5-15 days). The average duration of leukopenia was 5.5 days (95% CI = 4.2-6.7). 26.9% of the patients did not recover from leukopenia. Regression analysis showed no relationship between the duration of leukopenia and the dose of filgrastim. Conclusions: Filgrastim was able to regain the WBC counts in an appropriate period of time, allowing maintaining necessary drug treatments that otherwise would have been suspended